GCTK
GlucoTrack, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · IL
$2.97
−10.54%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
Market Cap
$2.09M
MomentumView details →
1D Return
−10.54%
YTD Return
−94.87%
RSI (14)
33.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
Market Cap
$2.09M
RSI (14)
33.0
MomentumView details →
1D Return
−10.54%
YTD Return
−94.87%
SummaryUpdated Jun 1, 2026
GlucoTrack, Inc. (NASDAQ:GCTK) is an Israeli medical device company founded in 2001 and headquartered in Or Yehuda, Israel. Originally established as Integrity Applications, Inc., the company rebranded to GlucoTrack in November 2021 to better reflect its focus on glucose monitoring technology. The company went public in April 2013 and specializes in developing non-invasive glucose monitoring devices for people with diabetes and pre-diabetes. Despite over two decades of development, GlucoTrack has yet to generate commercial revenue and remains in the research and development phase of bringing its flagship product to market.
Similar companies
Latest newsMore news →
Glucotrack, Inc. amended its 2026 equity line of credit common stock purchase agreement with White Lion Capital, LLC, setting the issuance of 2,505,513 Commitment Shares and adding a true-up payment mechanism, in connection with a $1,000,000 commitment fee.26d agoGlucotrack announced approximately $5.5 million in financing, including a $2.0 million equity offering priced at $0.75 per unit and a $3.5 million convertible debt investment from institutional investors.30d agoGlucotrack, through its subsidiary Lōkahi Therapeutics, announced the continued expansion of its ai² Futures Lab, which in its first year identified over 45 therapeutic opportunities on a budget of about $33,000 and advanced five into active discussions.35d ago